Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Adebrelimab and Radiation in mCRPC
NCT06251492Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fudan University. Primary endpoint: Disease Control Rate up to 24 months. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06251492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251492.